Immunocore Holdings PLC

Immunocore Holdings PLC

World Rank (Jan-05-2024)
4,182
Market Cap (Jan-05-2024)
3.200 Billion USD
World Rank (Jul-30-2023)
4,317
Market Cap (Jul-30-2023)
3.041 Billion USD
World Rank (Jan-07-2022)
8,234
Market Cap (Jan-07-2022)
1.260 Billion USD
World Rank (Jan-01-2021)
6,905
Company Rank in Country in 2023
Company rank in UK in July-2023 is 152
Headquarters Country
UK
Nasdaq / NYSE Code
IMCR
Market Cap (Mar-08-2026)
1.58
World Region
Europe
World Subregion
Northern Europe
Annual Revenue in USD
31 Million USD
Annual Net Income in USD
-154 Million USD
Annual Results for Period Ending
Dec-2021 ending year
Total Assets in USD
355 Million USD
Total Liabilities in USD
153 Million USD
Total Equity in USD
201 Million USD
Balance Sheet for Period Ending
Dec-2021 ending year
Business Sector
Healthcare
Biotechnology
Company Website
IMMUNOCORE HOLDINGS PLC
Yahoo
Yahoo @ Nasdaq
Company Profile

Immunocore is a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease. Headquarters is in UK.

Annual Results Summary

IMMUNOCORE HOLDINGS PLC - Yearly Revenue and Net Income - in Million GBP:

Year - EndingRevenueOperating IncomeNet Income
Dec-2022143-39 (Loss)41
Dec-202126-135 (Loss)-131 (Loss)
Dec-202030-89 (Loss)-74 (Loss)
Dec-201925-118 (Loss)-103 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 435 Million GBP.

Total Liabilities as on Dec-2022 was 156 Million GBP.

Total Equity as on Dec-2022 was 278 Million GBP.

IPO Year
2021
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share